X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs PIRAMAL ENTERPRISES - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD PIRAMAL ENTERPRISES ALEMBIC LTD/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 60.2 8.7 688.2% View Chart
P/BV x 3.4 2.9 117.1% View Chart
Dividend Yield % 0.3 0.8 39.3%  

Financials

 ALEMBIC LTD   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-16
PIRAMAL ENTERPRISES
Mar-17
ALEMBIC LTD/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs532,095 2.5%   
Low Rs291,025 2.9%   
Sales per share (Unadj.) Rs4.7492.8 1.0%  
Earnings per share (Unadj.) Rs8.872.6 12.1%  
Cash flow per share (Unadj.) Rs9.094.7 9.5%  
Dividends per share (Unadj.) Rs0.1521.00 0.7%  
Dividend yield (eoy) %0.41.3 27.1%  
Book value per share (Unadj.) Rs27.7862.5 3.2%  
Shares outstanding (eoy) m267.03172.56 154.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x8.73.2 274.8%   
Avg P/E ratio x4.721.5 21.8%  
P/CF ratio (eoy) x4.616.5 27.7%  
Price / Book Value ratio x1.51.8 81.9%  
Dividend payout %1.728.9 5.9%   
Avg Mkt Cap Rs m10,962269,194 4.1%   
No. of employees `000NA4.0 0.0%   
Total wages/salary Rs m23817,939 1.3%   
Avg. sales/employee Rs ThNM21,190.3-  
Avg. wages/employee Rs ThNM4,470.1-  
Avg. net profit/employee Rs ThNM3,120.0-  
INCOME DATA
Net Sales Rs m1,26085,037 1.5%  
Other income Rs m2642,338 11.3%   
Total revenues Rs m1,52487,374 1.7%   
Gross profit Rs m8334,991 0.2%  
Depreciation Rs m613,817 1.6%   
Interest Rs m020,310 0.0%   
Profit before tax Rs m28513,202 2.2%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m2,0960-   
Extraordinary Inc (Exp) Rs m-32-100 32.4%   
Tax Rs m62,281 0.3%   
Profit after tax Rs m2,34312,520 18.7%  
Gross profit margin %6.641.1 16.0%  
Effective tax rate %2.117.3 12.4%   
Net profit margin %185.914.7 1,262.5%  
BALANCE SHEET DATA
Current assets Rs m1,68987,590 1.9%   
Current liabilities Rs m486185,578 0.3%   
Net working cap to sales %95.4-115.2 -82.8%  
Current ratio x3.50.5 735.9%  
Inventory Days Days21731 698.9%  
Debtors Days Days8148 170.4%  
Net fixed assets Rs m1,624108,523 1.5%   
Share capital Rs m534345 154.8%   
"Free" reserves Rs m5,960148,481 4.0%   
Net worth Rs m7,404148,826 5.0%   
Long term debt Rs m104144,957 0.1%   
Total assets Rs m8,010482,394 1.7%  
Interest coverage x950.71.7 57,614.9%   
Debt to equity ratio x01.0 1.4%  
Sales to assets ratio x0.20.2 89.3%   
Return on assets %29.36.8 429.8%  
Return on equity %31.68.4 376.1%  
Return on capital %31.312.0 261.8%  
Exports to sales %2.90-   
Imports to sales %28.90-   
Exports (fob) Rs m37NA-   
Imports (cif) Rs m364NA-   
Fx inflow Rs m3715,001 0.2%   
Fx outflow Rs m3655,150 7.1%   
Net fx Rs m-3289,851 -3.3%   
CASH FLOW
From Operations Rs m346-100,393 -0.3%  
From Investments Rs m-48-24,202 0.2%  
From Financial Activity Rs m-301135,705 -0.2%  
Net Cashflow Rs m-311,110 -0.0%  

Share Holding

Indian Promoters % 64.0 52.9 121.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 4.0 5.0%  
FIIs % 9.7 26.6 36.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 16.5 158.2%  
Shareholders   54,701 93,274 58.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare ALEMBIC LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Jun 15, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 8-QTR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS